FiercePharma, by Angus Liu, Feb 13, 2019 Playing catch-up in the orphan drug field, China will cut the value-added tax rate for some rare-disease therapies by more than 80% in an effort to get new treatments to market faster. And multinational drugmakers are most likely to reap the benefits. Starting March 1, the value-added tax […]
FiercePharma, by Angus Liu, Jan 29, 2019 Pfizer has launched China’s first pay-for-performance program in oncology with its blockbuster breast cancer drug Ibrance, China Daily reported. Under the new program, called Bo’ai Xin’an, Pfizer promises reimbursement of up to 33.5% of Ibrance costs if an enrolled patient’s disease progresses within four months. The U.S. pharma set […]
January 7, 2016 – By Matthew Driskill in FiercePharmaAsia The Chinese government is expected to announce a precision medicine initiative in March that is expected to be over $9 Billion over 15 years – far beyond the $215 million U.S. plan announced last year. With that funding, many research projects around genome sequencing and specifically […]
China’s government issued new guidelines to centralize hospital procurements of all medicines by requiring them to obtain them only through provincial governments. The aim of the change was to reduce unnecessary expenses and safeguard against physician kickbacks. The guideline issued by the China cabinet, its State Council, excluded traditional Chinese medicine from the new requirements. […]